As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.

The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.

For researchers: If your study is not yet included in our portal, please contact the project management of the Clinical Trial Unit (angela.steinbach@uk-koeln.de or vassiliki.dimitriou@uk-koeln.de).

COVID-19 Remdesivir Compassionate Use

AcronymISRCTNEudraCTNCT (clinicaltrials.gov)DRKS

Remdesivir compassionate use program

Status: Active

Purpose / Objectives

Primary Outcome

Compassionate use program

Diagnosis

Patients with proven SARS-CoV-2 infection

Patient attributes

Inclusion criteria

Informed consent for compassionate use and healing attempt, if possible

Documents (password protected)

Responsibilities in overall trial

Gilead Sciences, Inc.

    National Coordinating Investigator

    Dr. med. Philipp Köhler